Last Update 10 Jul 26
Fair value Increased 5.26%NSIS B: Fair Outlook Will Rely On Probiotic Expansion In China
The analyst fair value estimate for Novozymes has been raised from DKK 380 to DKK 400, reflecting a series of higher Street price targets from multiple firms as analysts point to updated views on growth, margins and valuation for Novonesis.
Analyst Commentary
Recent Street research on Novozymes and Novonesis highlights a mix of optimism on long term potential and caution around execution and valuation risk. Several large banks have adjusted their price targets, with some focusing on upside scenarios and others stressing that the current valuation already prices in ambitious expectations for growth and margins.
At the more constructive end, JPMorgan lifted its Novonesis price target to DKK 520 and maintained a positive stance on the stock. Other firms have also raised targets into a DKK 460 to DKK 490 range, often paired with Buy or equivalent ratings. These views generally reference confidence in the combined entity and its positioning across enzymes and consumer ingredients, even if the specific growth drivers are not fully detailed in the research excerpts.
More neutral repositioning has also emerged. One large European bank moved Novonesis to Neutral from Underperform, taking its price target to DKK 415 from DKK 362, and explicitly pointing to valuation after a recent pullback in the stock. This suggests that, for some analysts, part of the perceived risk has already been absorbed into the share price, even if they are not prepared to take a more bullish stance.
There are also signs of recalibration at higher target levels. Morgan Stanley trimmed its price target on Novonesis to DKK 552 from DKK 560 while keeping an Overweight rating. The cut is modest in absolute terms, but it underlines that not all large houses are simply ratcheting targets higher without qualification, especially at levels that assume continued solid execution.
Bearish Takeaways
- Bearish analysts highlight that recent price targets in the DKK 500 plus range already embed demanding assumptions on growth and margins, which could leave Novozymes and Novonesis exposed if operational delivery or end market conditions fall short.
- The move from Underperform to Neutral at one firm, even with a higher DKK 415 target, signals that some see limited upside at current levels and prefer to stay on the sidelines rather than endorse a more optimistic risk reward profile.
- The reduction in the DKK 560 price target to DKK 552, while small, shows that even supportive analysts are willing to trim expectations at the margin, hinting at concerns that the valuation may be running ahead of what is currently visible on execution.
- Across the bearish commentary, the common thread is that the stock is sensitive to any disappointment on growth, integration of Novozymes within Novonesis or margin delivery, given that a number of target prices reflect relatively full expectations.
What’s in the News for Novozymes
- UndoAge signed a Memorandum of Understanding with Novonesis in Beijing on June 9 to deepen collaboration in probiotics and microbiome health, targeting high growth consumer areas such as stomach health, digestive wellness, and women’s intimate health. (Source: Key Developments)
- The partnership aims to commercialize Novonesis proprietary probiotic strains and solutions in China’s consumer health market, initially focusing on Pylopass based postbiotic products for stomach and digestive wellness and Urex based probiotic products for women’s microbiome health. (Source: Key Developments)
- Both companies plan to align scientific research with market ready applications by combining Novonesis microbial R&D and formulation support with UndoAge insights into Chinese consumer demand, with an emphasis on strain traceability, scientific evidence, and quality management. (Source: Key Developments)
- The collaboration is designed to support higher standards for probiotic products in China by improving product development transparency, ingredient traceability, and consumer communication, reflecting a sector shift toward science led and quality focused development. (Source: Key Developments)
Valuation Changes for Novozymes
- Fair Value: The analyst fair value estimate for Novozymes has moved from DKK 380 to DKK 400, indicating a modest upward adjustment in the assessed intrinsic value.
- Discount Rate: The discount rate has risen slightly from 5.63% to about 5.63%, a minimal change that suggests only a very small shift in the risk or return assumptions used in the model.
- Revenue Growth: Assumed € revenue growth has edged higher from about 6.12% to roughly 6.57%, pointing to a slightly stronger growth outlook in the updated framework.
- Profit Margin: Assumed € profit margin has eased from about 19.32% to roughly 18.98%, implying a small reduction in long term profitability expectations within the model.
- Future P/E: The future P/E multiple has been reduced from 35.90x to about 29.75x, indicating a lower valuation multiple applied to Novozymes forward earnings in the updated assessment.
Catalysts
About Novozymes
Novozymes develops and manufactures enzyme and microbial biosolutions that improve industrial productivity, support health applications and enable more sustainable production across multiple end markets.
What are the underlying business or industry changes driving this perspective?
- Although emerging markets are delivering double-digit volume growth helped by local labs and commercial teams, intensifying regional competition and potential regulatory hurdles in key countries could slow incremental share gains and cap the pace of top line expansion and operating leverage. This may limit upside to revenue growth and EBITDA margin.
- While rising global demand for high protein foods and advanced dairy solutions is driving strong adoption of new enzymes and cultures, increasing customer concentration and the risk that recent preloading in Dairy normalizes may dampen volume momentum and constrain future pricing power. This could temper revenue growth and gross margin expansion.
- Although bioenergy demand is benefitting from higher blend rates, ethanol capacity additions and early second-generation projects in India, Brazil and Europe, policy uncertainty and feedstock volatility could delay new projects and reduce utilization. This may restrict growth in Agriculture, Energy & Tech and moderate earnings growth.
- Despite tightening rules on microplastics and chemicals in detergents that favor enzymatic cleaning and support innovation-led growth in Household Care, weaker consumer volumes in developed markets and increased low-cost alternatives in emerging markets may limit mix upgrades and slow margin accretion. This could weigh on net margins.
- While human health and HMO applications are structurally supported by growing interest in probiotics and infant nutrition, slow regulatory processes in large markets such as China and the dilutive margin profile of newer platforms may prolong the payback period on R&D and commercial investments. This may delay any acceleration in earnings per share.
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more pessimistic perspective on Novozymes compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
- The bearish analysts are assuming Novozymes's revenue will grow by 6.6% annually over the next 3 years.
- The bearish analysts assume that profit margins will increase from 14.2% today to 19.0% in 3 years time.
- The bearish analysts expect earnings to reach €964.9 million (and earnings per share of €2.11) by about July 2029, up from €596.7 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as €1.2 billion.
- In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 29.8x on those 2029 earnings, down from 44.1x today. This future PE is greater than the current PE for the GB Chemicals industry at 18.6x.
- The bearish analysts expect the number of shares outstanding to decline by 0.55% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 5.63%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Stronger-than-expected secular demand for biosolutions across Food & Health and Planetary Health, combined with Novonesis' mid to high single digit organic sales growth guidance up to 2030 and current 8% organic growth, could support a structurally higher revenue trajectory and drive sustained earnings expansion.
- Ongoing mix shift toward high value platforms such as Human Health, HMOs and Advanced Protein Solutions, alongside scale benefits and synergies already lifting the adjusted EBITDA margin to 37.3%, may lead to further net margin expansion and faster earnings growth than currently implied.
- Early stage but strengthening regulatory and consumer trends such as bans on microplastics in detergents and demand for cleaner, low temperature washing formulations could accelerate Household Care adoption of enzymatic solutions, improving volumes, pricing power and net margins over time.
- Structural growth in bioenergy, including higher blend rates in India and Brazil, ramp up of second generation ethanol and biodiesel penetration, may unlock a longer runway of volume growth in Agriculture, Energy & Tech, supporting higher revenue and earnings resilience than assumed.
- Heavy and continuing investment in emerging markets, local labs and customer facing capabilities, together with still low penetration in categories such as cheese and high protein dairy in Asia, could lead to outsized volume growth and operating leverage, lifting revenue, EBITDA margin and earnings beyond a flat share price scenario.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bearish price target for Novozymes is DKK400.0, which represents up to two standard deviations below the consensus price target of DKK467.6. This valuation is based on what can be assumed as the expectations of Novozymes's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK552.0, and the most bearish reporting a price target of just DKK400.0.
- In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be €5.1 billion, earnings will come to €964.9 million, and it would be trading on a PE ratio of 29.8x, assuming you use a discount rate of 5.6%.
- Given the current share price of DKK422.4, the analyst price target of DKK400.0 is 5.6% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Novozymes?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
